Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Factory Mutual Insurance Co.

Factory Mutual Insurance Co. boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMNFree Report) by 85.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 141,000 shares of the life sciences company’s stock after purchasing an additional 64,800 shares during the period. Factory Mutual Insurance Co.’s holdings in Illumina were worth $19,633,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Acadian Asset Management LLC raised its position in shares of Illumina by 312.5% in the first quarter. Acadian Asset Management LLC now owns 2,013 shares of the life sciences company’s stock worth $702,000 after acquiring an additional 1,525 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Illumina by 3.1% in the first quarter. Dimensional Fund Advisors LP now owns 237,118 shares of the life sciences company’s stock worth $82,853,000 after acquiring an additional 7,114 shares during the period. Dakota Wealth Management raised its position in shares of Illumina by 13.8% in the first quarter. Dakota Wealth Management now owns 826 shares of the life sciences company’s stock worth $288,000 after acquiring an additional 100 shares during the period. Sequoia Financial Advisors LLC raised its position in shares of Illumina by 16.9% in the first quarter. Sequoia Financial Advisors LLC now owns 803 shares of the life sciences company’s stock worth $281,000 after acquiring an additional 116 shares during the period. Finally, Baird Financial Group Inc. raised its position in shares of Illumina by 10.2% in the first quarter. Baird Financial Group Inc. now owns 48,943 shares of the life sciences company’s stock worth $17,108,000 after acquiring an additional 4,548 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Jacob Thaysen acquired 7,330 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were bought at an average cost of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now owns 14,861 shares in the company, valued at approximately $2,010,544.69. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.13% of the stock is owned by company insiders.

Illumina Trading Up 1.5 %

NASDAQ:ILMN traded up $1.86 on Thursday, hitting $129.60. The stock had a trading volume of 467,335 shares, compared to its average volume of 1,758,456. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26. The stock has a market cap of $20.59 billion, a price-to-earnings ratio of -17.40 and a beta of 1.19. The company has a fifty day moving average price of $137.85 and a two-hundred day moving average price of $128.75. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $232.88.

Illumina (NASDAQ:ILMNGet Free Report) last released its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The company had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The firm’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.14 EPS. Equities research analysts expect that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Barclays upped their price objective on shares of Illumina from $50.00 to $80.00 and gave the stock an “underweight” rating in a research report on Thursday, January 25th. Stephens reissued an “overweight” rating and set a $170.00 target price on shares of Illumina in a research note on Wednesday, February 14th. Wolfe Research assumed coverage on shares of Illumina in a research note on Wednesday, December 13th. They set an “outperform” rating and a $175.00 target price for the company. Royal Bank of Canada reissued an “outperform” rating and set a $258.00 target price on shares of Illumina in a research note on Friday, February 9th. Finally, Guggenheim assumed coverage on shares of Illumina in a research note on Thursday, December 14th. They set a “buy” rating and a $155.00 target price for the company. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $166.95.

Check Out Our Latest Report on Illumina

About Illumina

(Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Featured Stories

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNFree Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.